Apigenin Side Effects

Reported Apigenin side effects

Apigenin is generally well-tolerated in both dietary and supplemental contexts. Common and uncommon adverse effects include: Gastrointestinal effects (most common): Mild nausea, bloating, or loose stools occur in a small percentage of users, typically mild and transient. Taking with food generally resolves symptoms. Severe gastrointestinal reactions are rare. Sedation and drowsiness: Apigenin's GABA-A activity can produce mild sedation, particularly at higher doses (500+ mg). Users should not operate heavy machinery or drive immediately after starting higher doses of apigenin supplementation. Chamomile tea rarely produces clinically significant sedation at culinary doses. Headache: Mild headache is reported occasionally, typically transient. Chamomile allergic reactions: Approximately 2-10% of adults have chamomile sensitization, usually presenting as contact dermatitis or allergic conjunctivitis. Systemic allergic reactions are rarer. Individuals with ragweed allergy, which shares cross-reactive proteins with chamomile, are at higher risk of chamomile sensitivity. Pure synthetic or isolated apigenin is less likely to produce allergic reactions than whole chamomile extracts because most chamomile allergens are proteins rather than small molecules. Bleeding risk with anticoagulants: Apigenin has mild antiplatelet activity and may theoretically enhance bleeding tendency in patients taking warfarin, clopidogrel, aspirin, or direct oral anticoagulants. Clinical significance at typical supplementation is likely modest but warrants awareness, particularly in polypharmacy contexts. Discontinue apigenin 7-10 days before surgical procedures. Estrogenic activity (hormone-sensitive conditions): Apigenin has weak phytoestrogen activity at high doses. Women with estrogen-dependent cancer history (breast, uterine) should consult their oncology team before supplementation. Clinical significance at culinary or modest supplementation doses is likely minimal. Drug interactions through CYP enzyme modulation: Apigenin can inhibit CYP1A2, CYP2C9, and CYP3A4 at high concentrations. Clinical relevance at typical oral supplementation is modest but theoretically could affect drugs with narrow therapeutic indices — warfarin, cyclosporine, tacrolimus, some chemotherapy agents. Thyroid function interactions: At high doses in animal models, apigenin has produced modest effects on thyroid hormone synthesis. Clinical significance in humans at typical supplementation doses has not been definitively characterized. Pregnancy and lactation: Apigenin safety during pregnancy has not been rigorously established in humans. Chamomile tea has traditional use during pregnancy but pharmaceutical doses are not recommended. Avoid high-dose apigenin supplementation during pregnancy or breastfeeding. Pediatric use: Pediatric safety and efficacy of purified apigenin have not been established. Chamomile tea is traditionally considered safe for children but pharmaceutical doses should be avoided. Surgical considerations: Due to antiplatelet and theoretical CYP effects, discontinue apigenin 7-10 days before surgical procedures. Interactions with GABAergic medications: Apigenin's GABA-A activity could theoretically enhance the effects of benzodiazepines, Z-drugs (zolpidem, zaleplon), alcohol, or other sedatives. Clinical significance at typical supplementation doses is modest but warrants caution. Avoid high-dose apigenin with benzodiazepines or sedative medications without physician guidance. Allergic cross-reactivity: Individuals with known Asteraceae family (daisy, ragweed, chrysanthemum) allergies should use chamomile and related apigenin sources cautiously. Liver function: Apigenin is not associated with hepatotoxicity at typical supplementation doses. Hepatic impairment does not typically require dose adjustment. Long-term safety: Dietary apigenin exposure has generational safe use data. Long-term (>1 year) purified apigenin supplementation data are less extensive but no major safety signals have emerged from available evidence. Overall tolerability grade: Excellent at culinary and modest supplementation doses. Generally good at higher doses (300-500 mg daily) with primary cautions being antiplatelet effects, sedation potential, and theoretical CYP interactions. No black-box-level safety concerns exist for healthy adults at typical supplementation.

When to continue, reduce, or stop Apigenin

Apigenin contraindications

Absolute contraindications: Known allergy to apigenin or Asteraceae family (chamomile, ragweed, daisy, chrysanthemum): Cross-reactivity with these plant families is common; allergic individuals should avoid chamomile-source apigenin and use cautious introduction of parsley- or passionflower-source apigenin. Pregnancy (high-dose supplementation): Safety data lacking; avoid pharmaceutical-dose apigenin. Dietary chamomile tea has traditional use during pregnancy but should be moderated. Lactation (high-dose supplementation): Safety data lacking; avoid pharmaceutical-dose supplementation. Relative contraindications (discuss with physician before use): Anticoagulation therapy (warfarin, direct oral anticoagulants, clopidogrel): Mild antiplatelet effects may improve bleeding risk at high supplementation doses; physician discussion recommended. Concurrent benzodiazepine or Z-drug therapy: Theoretical additive GABA-A effects; avoid high-dose apigenin, limit to chamomile tea. Concurrent alcohol use (chronic heavy use): Theoretical additive CNS depression at high doses of both; moderate with caution. Hormone-dependent cancer history (estrogen-receptor-positive breast cancer, endometrial cancer): Weak phytoestrogen activity; consult oncology team before high-dose supplementation. Upcoming surgical procedures: Discontinue apigenin 7-10 days before surgery to minimize bleeding risk. Concurrent chemotherapy (particularly tyrosine kinase inhibitors, some cytotoxic agents): Potential drug interactions via CYP and transporter modulation; discuss with oncology team. Severe hepatic impairment: Limited clinical data; theoretical concerns about altered metabolism. Cyclosporine, tacrolimus therapy: Potential CYP3A4 inhibition could increase drug levels; avoid or use with drug level monitoring. Caution populations: Adults over 75 years: Monitor for sedation or orthostatic effects; start at lower doses. Users with multiple polypharmacy agents: Theoretical CYP modulation across multiple drug classes warrants physician awareness of supplementation. Users operating heavy machinery or driving: Avoid higher apigenin doses during periods requiring alertness; preference for evening dosing. Chronic kidney or liver disease: No specific dose adjustment documented but warrants clinical oversight. Drug interactions requiring monitoring: Warfarin, DOACs (theoretical enhanced bleeding risk) Benzodiazepines, Z-drugs (theoretical additive sedation) Cyclosporine, tacrolimus (theoretical CYP3A4 inhibition) Some chemotherapy agents (theoretical CYP modulation) Antihypertensives (theoretical modest additive effects) Aromatase inhibitor therapy (theoretical interference) Discontinue immediately and seek medical attention if: Severe allergic reaction (rash, difficulty breathing, facial swelling) Significant unexplained bleeding or bruising Severe unexplained sedation or respiratory depression Jaundice or severe abdominal pain suggestive of hepatic dysfunction

Why vendor quality drives Apigenin side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Apigenin side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .